Effects of menopause and hormone replacement therapy on serum levels of coenzyme Q10 and other lipid-soluble antioxidants

BioFactors

Volumn 25, Issue 1-4, 2005, Pages 61-66

  Palan, Prabhudas R ^a   Connell, Kathleen ^b   Ramirez, Elizabeth ^a   Inegbenijie, Christian ^a   Gavara, Rachana Y ^a   Ouseph, Jacob A ^a   Mikhail, Magdy S ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antioxidants; Coenzyme Q10; Hormone replacement therapy; Menopause; Tocopherols

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; BETA CAROTENE; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; GAMMA TOCOPHEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LYCOPENE; OXYGEN; TRIACYLGLYCEROL; UBIDECARENONE;

ADULT; AGED; ANTIOXIDANT ACTIVITY; BIOENERGY; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DETERMINATION; ENZYME BLOOD LEVEL; FEMALE; HEART PROTECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORMONE SUBSTITUTION; HUMAN; LIPID ANALYSIS; LIPID SOLUBILITY; MENOPAUSE; MITOCHONDRIAL RESPIRATION; OXYGEN CONCENTRATION; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY CHAIN; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN BLOOD LEVEL;

EID: 33746104460     PISSN: 09516433     EISSN: None     Source Type: Journal    
DOI: 10.1002/biof.5520250107     Document Type: Conference Paper

References (29)

1. R.N. Anderson, Deaths: leading causes for 1999, National Vital Statistics Reports 49 (2001), 1-87.
2. G. Samsioe, HRT and cardiovascular disease, Ann NY Acad Sci 997 (2003), 358-372.
3. J.E. Rossouw, G.L. Anderson, R.L. Prentice et al., Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial, JAMA 288 (2002), 321-333.
4. J.A. Simon, J. Hsia, J.A. Cauley et al., Postmenopausal hormone therapy and risk of stroke: The heart and estrogen-progestin replacement study, Circulation 103 (2001), 638-642.
5. L. Humphrey, B. Chan and H. Sox, Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease, Ann Intern Med 137 (2002), 273-284.
6. M.P. Warren and S. Halpert, Hormone replacement therapy: controversies, pros and cons, Best Practice & Research Clinical Endocrinol & Metabolism 18 (2004), 317-332.
7. B. Molavi and J.L. Mehta, Oxidative stress in cardiovascular disease: molecular basis of its deleterious effects, its detection, and therapeutic considerations, Curr Opinion Cardio 19 (2004), 488-493.
8. R. Stocker and J.F. Keaney Jr, Role of oxidative modifications in atherosclerosis, Physiol Rev 84 (2004), 1381-1478.
9. R. Stocker, V.W. Bowry and B. Frei, Ubiquinol-10 protects human low density lipoprotein more efficiently against lipid peroxidation than does α-tocopherol, Proc Natl Acad Sci USA 88 (1991), 1646-1650.
10. 10 and vitamin E on the peroxdation of human low density lipoprotein sub-fractions, Proc Natl Acad Sci USA 92 (1995), 9388-9391.
11. 10 and cardiovascular health, Altern Ther Health Med 10 (2004), 22-30.
12. 10: an update, Curr Opin Clin Nutr Metab Care 8 (2005), 641-646.
13. 10 and cardiovascular disease: a review, J Cardiovasc Nurs 16 (2002), 9-20.
14. A. Azzi, R. Gysin, P. Kempna et al., The role of α-tocopherol in preventing disease: from epidemiology to molecular events, Mol Aspects Med 24 (2003), 325-336.
15. M. Turunen, E. Swiezewska, T. Chojnacki, P. Sindelar and G Dallner, Regulatory aspects of coenzyme Q metabolism, Free Radiac Res 36 (2002), 437-443.
16. 10, Biochim Biophys Acta (2004), 171-199.
17. G. Dallner and P.J. Sindelar, Regulation of ubiquinone metabolism, Free Radical Biology & Med 29 (2000), 285-294.
18. S. Ozden, K. Dildar, Y.H. Kadir and K. Gulizar, The effects of hormone replacement therapy on lipid peroxidation and antioxidant status, Maturitas 38 (2001), 165-170.
19. C. Hermenegildo, M.C. Garcia-Martinez, J.J. Tarin, A. Llacer and A. Cano, The effects of oral hormone replacement therapy on lipoprotein profile, resistance of LDL to oxidation and LDL particle size, Maturitas 38 (2001), 287-295.
20. 10 and tocopherols in cervical intraepithelial neoplasia and cervical cancer, Eur J Cancer Prev 12 (2003), 321-326.
21. P.R. Palan, M.S. Mikhail, G.L. Goldberg et al., Plasma levels of β-carotene, lycopene, canthaxantin, retinal, α-tocopherol and γ-tocopherol in cervical intraepithelial neoplasia, Clin Cancer Res 2 (1996), 181-185.
22. L. Ernster and G. Dallner, Biochemical, physiological and medical aspects of ubiquinone function, Biochim Biophys Acta 24 (1995), 195-204.
23. 10 concentrations and redox state in apparently healthy children and adults, Clinica Chimica Acta 343 (2004), 139-144.
24. A.H.M. Rijpkema, A.A. van der Sanden and A.H.C. Ruijs, Effects of postmenopausal estrogen-progestogen replacement therapy on serum lipids and lipoproteins: a review, Maturitas 12 (1990), 259-285.
25. 10 changes are associated with metabolic syndrome, Clinica Chimica Acta 344 (2004), 173-179.
26. 10 ratio as a possible marker of increased risk for atherosclerosis, Biofactors 9 (1999), 231-240.
27. 10 in cardiovascular disease, Biofactors 9 (1999), 273-284.
28. J.K. Wilcox, S.L. Ash and G.L Catignani, Antioxidants and prevention of chronic disease, Critic Rev Food Sci Nutr 44 (2004), 275-295.
29. 10, J Am College Nutr 20 (2001), 591-598.